Praxis Precision Medicines, Inc. (PRAX)
NASDAQ:PRAX
Want to see PRAX full AI Analyst Report?
PRAX Stock Chart & Stats
$342.50
-$2.82(-3.64%)
At close: 4:00 PM EST
$342.50
-$2.82(-3.64%)
Day’s Range― - ―
52-Week Range$37.19 - $366.52
Previous CloseN/A
Volume51.58K
Average Volume (3M)483.97K
Market Cap
$7.87B
Enterprise Value$5.17B
Total Cash (Recent Filing)$786.87M
Total Debt (Recent Filing)$1.44M
Price to Earnings (P/E)―
Beta2.18
Next Earnings
Aug 10, 2026EPS Estimate
-3.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.39
Shares Outstanding27,878,775
10 Day Avg. Volume524,032
30 Day Avg. Volume483,971
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)7.55
Price to Sales (P/S)0.00
P/FCF Ratio-26.63
Enterprise Value/Market Cap0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-40.15
Enterprise Value/Ebitda-15.85
Forecast
1Y Price Target
$613.56Price Target Upside79.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)-15.22
Revenue Forecast (FY)$4.54M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And Multi-year RunwayA $1.4B cash position provides durable financial flexibility to fund late‑stage trials, regulatory activities and launch builds into 2028. This reduces near‑term financing pressure, supports multiple concurrent programs and increases optionality around partnering or commercialization choices.
Regulatory Progress With Accepted NDAs And Set PDUFA DatesNDA acceptances with defined PDUFA dates materially de‑risk timing and create clear regulatory catalysts. Successful reviews could transition Praxis from clinical to commercial stage, validating programs and enabling revenue generation or more attractive partnerships in a lasting way.
Compelling Clinical Efficacy Signal And Diversified Late‑stage PipelineA 77% placebo‑adjusted seizure reduction in EMBRAVE Part A is a strong efficacy signal for a rare genetic epilepsy, bolstering approval prospects and scientific validation of the platform. Combined with four late‑stage assets, this strengthens long‑term commercial potential across neurology indications.
Bears Say
Rising Operating Cash BurnA 62% YoY increase in quarterly operating cash use reflects higher R&D and commercial investment. Persistently elevated burn increases the likelihood of future financing, which can dilute shareholders and create execution risk if regulatory or launch timing slips over a multi‑quarter horizon.
No Meaningful Revenue And Widening Net LossesZero near‑term revenues and widening losses indicate structural unprofitability typical of clinical biotechs. This makes the company reliant on external capital until product approvals and commercialization, prolonging funding risk and limiting positive free cash flow for multiple quarters or years.
Clinical Setbacks And Program ReassessmentA primary endpoint miss and paused enrollment signal meaningful program risk and potential delays. Reassessment can change timelines, increase costs, or reduce peak probability of success for that asset, materially affecting portfolio value and resource allocation over the medium term.
Praxis Precision Medicines News
PRAX FAQ
What was Praxis Precision Medicines, Inc.’s price range in the past 12 months?
Praxis Precision Medicines, Inc. lowest stock price was $37.19 and its highest was $366.52 in the past 12 months.
What is Praxis Precision Medicines, Inc.’s market cap?
Praxis Precision Medicines, Inc.’s market cap is $7.87B.
When is Praxis Precision Medicines, Inc.’s upcoming earnings report date?
Praxis Precision Medicines, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 49 days.
How were Praxis Precision Medicines, Inc.’s earnings last quarter?
Praxis Precision Medicines, Inc. released its earnings results on May 07, 2026. The company reported -$3.2 earnings per share for the quarter, beating the consensus estimate of -$3.589 by $0.389.
Is Praxis Precision Medicines, Inc. overvalued?
According to Wall Street analysts Praxis Precision Medicines, Inc.’s price is currently Undervalued.
Does Praxis Precision Medicines, Inc. pay dividends?
Praxis Precision Medicines, Inc. does not currently pay dividends.
What is Praxis Precision Medicines, Inc.’s EPS estimate?
Praxis Precision Medicines, Inc.’s EPS estimate is -3.67.
How many shares outstanding does Praxis Precision Medicines, Inc. have?
Praxis Precision Medicines, Inc. has 27,878,775 shares outstanding.
What happened to Praxis Precision Medicines, Inc.’s price movement after its last earnings report?
Praxis Precision Medicines, Inc. reported an EPS of -$3.2 in its last earnings report, beating expectations of -$3.589. Following the earnings report the stock price went down -1.417%.
Which hedge fund is a major shareholder of Praxis Precision Medicines, Inc.?
Currently, no hedge funds are holding shares in PRAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Praxis Precision Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$613.56 (79.14% Upside)
$613.56 (79.14% Upside)
Blogger Sentiment
Bullish
PRAX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 832.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
556.99%
12-Months-Change
Fundamentals
Return on Equity
-43.02%
Trailing 12-Months
Asset Growth
205.01%
Trailing 12-Months
Company Description
Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
PRAX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational and clinical momentum: two NDAs accepted with PDUFA dates, rapid completion of a key EMBOLD study, an impressive 77% placebo‑adjusted seizure reduction in EMBRAVE Part A, multiple upcoming pivotal readouts, and a strengthened balance sheet ($1.4B, +51% vs. year‑end). Management is heavily investing in commercialization and late‑stage development (Q1 operating cash use +62% YoY), which raises short‑term cash burn and execution risk. Regulatory timing, heterogeneous populations in broad DEE, and U.S. pricing dynamics are notable uncertainties but are framed as manageable. On balance, the positive clinical data, regulatory progress, and substantial cash runway outweigh the cost and execution risks.View all PRAX earnings summariesPRAX Stock 12 Month Forecast
Average Price Target
$613.56
▲(79.14% Upside)
Technical Analysis
ARS Pharmaceuticals
―
AbCellera Biologics
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Septerna, Inc.
―
Ownership Overview
8.15% Insiders
25.37% Mutual Funds
51.61% Other Institutional Investors
0.27% Public Companies and Individual Investors